Palisade Bio, Inc. (PALI) 10-Year Financial Performance & Capital Metrics

PALI • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutPalisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.Show more

Revenue $0 -100.0%
EBITDA -$15M -13.7%
Net Income -$14M -17.4%
EPS (Diluted) -10.19 +62.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -153.55% -48.5%
ROIC -
Debt/Equity 0.02 -30.8%
Interest Coverage -1238.25 -42.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 95 (top 5%)
✓Trading at only 0.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM20.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM82.84%

ROCE

10Y Avg-897.81%

5Y Avg-1674.11%

3Y Avg-133.85%

Latest-155.51%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	2.01B	15.23	387.53	33.97%	29.28%	21.28%	2.2%	0.21
ARGXargenx SE	49.47B	799.33	62.55	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.74	54.83	15.54%	32.78%	12.61%	12.77%	0.65
GLPGGalapagos N.V.	2.25B	34.12	30.46	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.33B	85.23	20.15	6.24%	21.94%	7.11%	3.43%	0.02
ALMSAlumis Inc. Common Stock	2.86B	24.34	-2.34		-11.08%	-63.71%		0.12
ZBIOZenas BioPharma, Inc.	1.21B	22.56	-6	-90%	-12.66%	-96.68%		0.00
ORKAOruka Therapeutics, Inc.	1.55B	32.00	-6.41			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	10.42K	16.25K	260K	260K	15.39K	0	0	0	250K	0
Revenue Growth %	-0.45%	0.56%	15%	0%	-0.94%	-1%	-	-	-	-1%
Cost of Goods Sold+	0	0	0	-990K	0	146K	0	0	0	0
COGS % of Revenue	-	-	-	-3.81%	-	-	-	-	-	-
Gross Profit+	10.42K	16.25K	260K	1.25M	15.39K	-146K	0	0	250K	0
Gross Margin %	1%	1%	1%	4.81%	1%	-	-	-	1%	-
Gross Profit Growth %	-0.45%	0.56%	15%	3.81%	-0.99%	-10.48%	1%	-	-	-1%
Operating Expenses+	19.17M	20.65M	13.57M	8.52M	8.65M	9.15M	41.85M	15.72M	13.32M	14.86M
OpEx % of Revenue	1839.97%	1271.27%	52.18%	32.77%	561.71%	-	-	-	53.28%	-
Selling, General & Admin	6.18M	7M	5.18M	4.37M	4.44M	6.05M	9.31M	8.76M	6.2M	5.8M
SG&A % of Revenue	593.65%	431%	19.93%	16.82%	288.55%	-	-	-	24.81%	-
Research & Development	12.64M	12.84M	8M	3.96M	4.06M	3.1M	2.43M	6.55M	6.89M	9.06M
R&D % of Revenue	1213.11%	790.59%	30.78%	15.23%	263.8%	-	-	-	27.57%	-
Other Operating Expenses	0	0	0	0	0	0	30.12M	410K	225K	0
Operating Income+	-19.16M	-20.17M	-13.21M	-8.26M	-8.63M	-9.3M	-41.85M	-15.72M	-13.07M	-14.86M
Operating Margin %	-1839.01%	-1241.35%	-50.83%	-31.77%	-560.74%	-	-	-	-52.28%	-
Operating Income Growth %	-0.1%	-0.05%	0.34%	0.38%	-0.05%	-0.08%	-3.5%	0.62%	0.17%	-0.14%
EBITDA+	-18.81M	-19.83M	-12.93M	-8.07M	-8.49M	-9.15M	-41.85M	-15.72M	-13.07M	-14.86M
EBITDA Margin %	-1805.85%	-1220.58%	-49.71%	-31.05%	-551.39%	-	-	-	-52.26%	-
EBITDA Growth %	-0.1%	-0.05%	0.35%	0.38%	-0.05%	-0.08%	-3.57%	0.62%	0.17%	-0.14%
D&A (Non-Cash Add-back)	345.46K	337.51K	289.21K	185.8K	143.86K	146K	2K	3K	4K	3K
EBIT	-19.09M	-19.93M	-15.51M	-4.92M	-8.34M	-10.09M	-24.22M	-14.25M	-12.29M	-14.43M
Net Interest Income+	-1.75M	-1.08M	-88.8K	71.08K	58.81K	-235K	-2.4M	0	-15K	-12K
Interest Income	69.55K	58.84K	70.27K	78.78K	67.73K	0	0	13K	0	0
Interest Expense	1.82M	1.14M	159.07K	7.7K	8.92K	235K	2.4M	13K	15K	12K
Other Income/Expense	-1.75M	-908K	-2.45M	3.33M	280.04K	-1.02M	15.24M	1.46M	770K	421K
Pretax Income+	-20.9M	-21.07M	-15.67M	-4.92M	-8.35M	-10.32M	-26.62M	-14.26M	-12.3M	-14.44M
Pretax Margin %	-2006.72%	-1297.24%	-60.25%	-18.94%	-542.55%	-	-	-	-49.2%	-
Income Tax+	68.83K	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-20.9M	-21.07M	-15.67M	-4.92M	-8.35M	-10.32M	-26.62M	-14.26M	-12.3M	-14.44M
Net Margin %	-2006.72%	-1297.24%	-60.25%	-18.94%	-542.55%	-	-	-	-49.2%	-
Net Income Growth %	0.08%	-0.01%	0.26%	0.69%	-0.7%	-0.24%	-1.58%	0.46%	0.14%	-0.17%
Net Income (Continuing)	-20.9M	-21.07M	-15.67M	-4.92M	-8.35M	-10.32M	-26.62M	-14.26M	-12.3M	-14.44M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-197.36	-126.11	-71.34	-18.02	-35.18	-186.00	-2546.10	-16.53	-27.01	-10.19
EPS Growth %	0.12%	0.36%	0.43%	0.75%	-0.95%	-4.29%	-12.69%	0.99%	-0.63%	0.62%
EPS (Basic)	-197.36	-126.11	-71.59	-18.02	-14.78	-186.00	-2144.25	-16.53	-27.01	-10.19
Diluted Shares Outstanding	105.92K	8.35K	219.6K	273.24K	237.39K	237.39K	12.46K	880.3K	456.01K	1.42M
Basic Shares Outstanding	105.92K	8.35K	218.84K	273.24K	122.41K	832.3K	12.41K	880.1K	456.01K	1.42M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.43M	20.9M	12.45M	6.51M	5.65M	896K	11.51M	14.73M	13.33M	10.49M
Cash & Short-Term Investments	12.23M	20.19M	11.67M	5.79M	5.11M	729K	10.49M	12.38M	12.43M	9.82M
Cash Only	4.72M	15.19M	6.67M	5.79M	5.11M	713K	10.49M	12.38M	12.43M	9.82M
Short-Term Investments	7.52M	5M	5M	0	0	16K	0	0	0	0
Accounts Receivable	37.32K	63.57K	371.59K	358K	21.06K	0	150K	1.44M	148K	24K
Days Sales Outstanding	1.31K	1.43K	521.65	502.57	499.44	-	-	-	216.08	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	100K	0	114K	112K	87K
Total Non-Current Assets+	1.52M	1.7M	1.44M	1.18M	937.01K	2.12M	1.01M	1.03M	724K	386K
Property, Plant & Equipment	343.2K	269.56K	172.89K	90.31K	242.74K	280K	112K	310K	208K	87K
Fixed Asset Turnover	0.03x	0.06x	1.50x	2.88x	0.06x	-	-	-	1.20x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.1M	990.15K	883.46K	763.54K	668.94K	0	0	0	0	0
Long-Term Investments	0	424.24K	365.46K	298.24K	0	0	0	26K	0	26K
Other Non-Current Assets	71.8K	15.66K	13.85K	23.96K	25.34K	1.84M	894K	694K	516K	273K
Total Assets+	14.95M	22.6M	13.88M	7.68M	6.58M	3.02M	12.51M	15.76M	14.05M	10.88M
Asset Turnover	0.00x	0.00x	0.02x	0.03x	0.00x	-	-	-	0.02x	-
Asset Growth %	-0.5%	0.51%	-0.39%	-0.45%	-0.14%	-0.54%	3.14%	0.26%	-0.11%	-0.23%
Total Current Liabilities+	6.43M	7.33M	1.51M	1.05M	1.22M	8.08M	2.5M	3.01M	2.59M	3.24M
Accounts Payable	1.46M	2.34M	875.07K	832.56K	824.41K	2.54M	1.52M	1.76M	698K	1.1M
Days Payables Outstanding	-	-	-	-306.96	-	6.34K	-	-	-	-
Short-Term Debt	4.63M	3.71M	0	0	0	1.05M	87K	88K	158K	79K
Deferred Revenue (Current)	0	0	0	-1000K	0	0	0	0	0	0
Other Current Liabilities	173.54K	430.74K	220.88K	-756.4K	124.67K	0	511K	574K	831K	0
Current Ratio	2.09x	2.85x	8.22x	6.19x	4.61x	0.11x	4.61x	4.89x	5.15x	3.24x
Quick Ratio	2.09x	2.85x	8.22x	6.19x	4.61x	0.11x	4.61x	4.89x	5.15x	3.24x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.56M	3.94M	3.85M	583.73K	233.14K	2.04M	2.65M	272K	153K	152K
Long-Term Debt	3.38M	0	0	535K	0	94K	0	0	0	0
Capital Lease Obligations	0	0	0	0	148.54K	112K	0	211K	90K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	174.14K	3.94M	3.85M	48.73K	84.59K	1.83M	2.65M	61K	63K	152K
Total Liabilities	9.98M	11.27M	5.37M	1.63M	1.46M	10.12M	5.15M	3.28M	2.74M	3.39M
Total Debt+	7.93M	3.71M	0	5.04M	288.54K	1.42M	199K	404K	369K	169K
Net Debt	3.21M	-11.49M	-6.67M	-749.11K	-4.83M	708K	-10.3M	-11.98M	-12.06M	-9.65M
Debt / Equity	1.60x	0.33x	-	0.83x	0.06x	-	0.03x	0.03x	0.03x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10.55x	-17.67x	-83.08x	-1072.88x	-967.71x	-39.56x	-17.45x	-1209.31x	-871.33x	-1238.25x
Total Equity+	4.97M	11.33M	8.52M	6.05M	5.13M	-7.1M	7.37M	12.48M	11.31M	7.49M
Equity Growth %	-0.72%	1.28%	-0.25%	-0.29%	-0.15%	-2.38%	2.04%	0.69%	-0.09%	-0.34%
Book Value per Share	46.90	1357.79	38.78	22.14	21.59	-29.90	590.95	14.18	24.81	5.29
Total Shareholders' Equity	4.97M	11.33M	8.52M	6.05M	5.13M	-7.1M	7.37M	12.48M	11.31M	7.49M
Common Stock	70.77K	110.33K	151.6K	182.05K	38.66K	28K	3K	30K	93K	27K
Retained Earnings	-171.96M	-193.03M	-208.7M	-213.62M	-221.98M	-68.03M	-94.64M	-109.19M	-121.51M	-135.94M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	3.07K	3.9K	2.63K	-413	-6.19K	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.93M	-15.62M	-13.42M	-7.69M	-7.26M	-4.77M	-14.77M	-13.36M	-11.13M	-12.19M
Operating CF Margin %	-1817.38%	-961.23%	-51.6%	-29.59%	-471.33%	-	-	-	-44.53%	-
Operating CF Growth %	-0.62%	0.18%	0.14%	0.43%	0.06%	0.34%	-2.1%	0.1%	0.17%	-0.1%
Net Income	-20.9M	-21.07M	-15.67M	-4.92M	-8.35M	-10.32M	-26.62M	-14.26M	-12.3M	-14.44M
Depreciation & Amortization	345.46K	337.51K	289.21K	185.8K	143.86K	3K	2K	3K	4K	3K
Stock-Based Compensation	2.95M	3.45M	1.77M	1.09M	0	2.01M	1.89M	1.03M	624K	652K
Deferred Taxes	0	0	0	0	0	-38K	0	0	0	0
Other Non-Cash Items	5.37M	3.86M	6.47M	-2.29M	743.83K	1.19M	14.71M	-1.39M	139K	199K
Working Capital Changes	-2.2M	1.51M	-2.15M	-336.88K	208.28K	2.39M	-4.76M	1.25M	400K	1.39M
Change in Receivables	188.21K	-450.5K	-249.23K	80.81K	272.99K	-59K	84K	0	0	0
Change in Inventory	0	-7.91M	-11.75M	36.99K	0	-947K	0	0	0	0
Change in Payables	-1.05M	879.08K	-1.52M	-36.99K	-15.74K	1.01M	0	399K	-492K	818K
Cash from Investing+	7.25M	2.36M	-94.05K	5M	0	-6K	-54K	-10K	-4K	0
Capital Expenditures	-243.58K	-161.11K	-94.05K	-1.71K	0	-6K	0	-10K	-4K	0
CapEx % of Revenue	23.38%	9.92%	0.36%	0.01%	-	-	-	-	0.02%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-67.31K	-63.03K	-82.64K	0	0	0	0	0	0	0
Cash from Financing+	3.89M	23.74M	4.99M	1.81M	6.59M	1.89M	24.61M	15.26M	11.19M	9.58M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-847.05K	0	0	0	0	-87K	-317K	1.65M	2.16M	1.57M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.18M	-15.78M	-13.51M	-7.69M	-7.26M	-4.77M	-14.77M	-13.37M	-11.14M	-12.19M
FCF Margin %	-1840.77%	-971.15%	-51.96%	-29.59%	-471.33%	-	-	-	-44.55%	-
FCF Growth %	-0.56%	0.18%	0.14%	0.43%	0.06%	0.34%	-2.09%	0.09%	0.17%	-0.09%
FCF per Share	-181.04	-1890.62	-61.52	-28.16	-30.56	-20.11	-1185.35	-15.19	-24.42	-8.61
FCF Conversion (FCF/Net Income)	0.91x	0.74x	0.86x	1.56x	0.87x	0.46x	0.56x	0.94x	0.91x	0.84x
Interest Paid	0	0	0	0	0	0	64K	0	0	14K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-184.28%	-258.62%	-157.88%	-67.63%	-149.47%	-	-20012.03%	-143.72%	-103.4%	-153.55%
Return on Invested Capital (ROIC)	-129.64%	-377.18%	-1178.64%	-173.49%	-231.21%	-	-	-	-	-
Gross Margin	100%	100%	100%	480.77%	100%	-	-	-	100%	-
Net Margin	-200671.98%	-129724.24%	-6025.38%	-1894.23%	-54254.9%	-	-	-	-4920%	-
Debt / Equity	1.60x	0.33x	-	0.83x	0.06x	-	0.03x	0.03x	0.03x	0.02x
Interest Coverage	-10.55x	-17.67x	-83.08x	-1072.88x	-967.71x	-39.56x	-17.45x	-1209.31x	-871.33x	-1238.25x
FCF Conversion	0.91x	0.74x	0.86x	1.56x	0.87x	0.46x	0.56x	0.94x	0.91x	0.84x
Revenue Growth	-44.69%	55.96%	1500.39%	0%	-94.08%	-100%	-	-	-	-100%

Frequently Asked Questions

Growth & Financials

Palisade Bio, Inc. (PALI) saw revenue decline by 100.0% over the past year.

Palisade Bio, Inc. (PALI) reported a net loss of $11.2M for fiscal year 2024.

Dividend & Returns

Palisade Bio, Inc. (PALI) has a return on equity (ROE) of -153.6%. Negative ROE indicates the company is unprofitable.

Palisade Bio, Inc. (PALI) had negative free cash flow of $10.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Palisade Bio, Inc. (PALI) 10-Year Financial Performance & Capital Metrics

PALI • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0 -100.0%
EBITDA -$15M -13.7%
Net Income -$14M -17.4%
EPS (Diluted) -10.19 +62.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -153.55% -48.5%
ROIC -
Debt/Equity 0.02 -30.8%
Interest Coverage -1238.25 -42.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 95 (top 5%)
✓Trading at only 0.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM20.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM82.84%

ROCE

10Y Avg-897.81%

5Y Avg-1674.11%

3Y Avg-133.85%

Latest-155.51%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	2.01B	15.23	387.53	33.97%	29.28%	21.28%	2.2%	0.21
ARGXargenx SE	49.47B	799.33	62.55	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.74	54.83	15.54%	32.78%	12.61%	12.77%	0.65
GLPGGalapagos N.V.	2.25B	34.12	30.46	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.33B	85.23	20.15	6.24%	21.94%	7.11%	3.43%	0.02
ALMSAlumis Inc. Common Stock	2.86B	24.34	-2.34		-11.08%	-63.71%		0.12
ZBIOZenas BioPharma, Inc.	1.21B	22.56	-6	-90%	-12.66%	-96.68%		0.00
ORKAOruka Therapeutics, Inc.	1.55B	32.00	-6.41			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	10.42K	16.25K	260K	260K	15.39K	0	0	0	250K	0
Revenue Growth %	-0.45%	0.56%	15%	0%	-0.94%	-1%	-	-	-	-1%
Cost of Goods Sold+	0	0	0	-990K	0	146K	0	0	0	0
COGS % of Revenue	-	-	-	-3.81%	-	-	-	-	-	-
Gross Profit+	10.42K	16.25K	260K	1.25M	15.39K	-146K	0	0	250K	0
Gross Margin %	1%	1%	1%	4.81%	1%	-	-	-	1%	-
Gross Profit Growth %	-0.45%	0.56%	15%	3.81%	-0.99%	-10.48%	1%	-	-	-1%
Operating Expenses+	19.17M	20.65M	13.57M	8.52M	8.65M	9.15M	41.85M	15.72M	13.32M	14.86M
OpEx % of Revenue	1839.97%	1271.27%	52.18%	32.77%	561.71%	-	-	-	53.28%	-
Selling, General & Admin	6.18M	7M	5.18M	4.37M	4.44M	6.05M	9.31M	8.76M	6.2M	5.8M
SG&A % of Revenue	593.65%	431%	19.93%	16.82%	288.55%	-	-	-	24.81%	-
Research & Development	12.64M	12.84M	8M	3.96M	4.06M	3.1M	2.43M	6.55M	6.89M	9.06M
R&D % of Revenue	1213.11%	790.59%	30.78%	15.23%	263.8%	-	-	-	27.57%	-
Other Operating Expenses	0	0	0	0	0	0	30.12M	410K	225K	0
Operating Income+	-19.16M	-20.17M	-13.21M	-8.26M	-8.63M	-9.3M	-41.85M	-15.72M	-13.07M	-14.86M
Operating Margin %	-1839.01%	-1241.35%	-50.83%	-31.77%	-560.74%	-	-	-	-52.28%	-
Operating Income Growth %	-0.1%	-0.05%	0.34%	0.38%	-0.05%	-0.08%	-3.5%	0.62%	0.17%	-0.14%
EBITDA+	-18.81M	-19.83M	-12.93M	-8.07M	-8.49M	-9.15M	-41.85M	-15.72M	-13.07M	-14.86M
EBITDA Margin %	-1805.85%	-1220.58%	-49.71%	-31.05%	-551.39%	-	-	-	-52.26%	-
EBITDA Growth %	-0.1%	-0.05%	0.35%	0.38%	-0.05%	-0.08%	-3.57%	0.62%	0.17%	-0.14%
D&A (Non-Cash Add-back)	345.46K	337.51K	289.21K	185.8K	143.86K	146K	2K	3K	4K	3K
EBIT	-19.09M	-19.93M	-15.51M	-4.92M	-8.34M	-10.09M	-24.22M	-14.25M	-12.29M	-14.43M
Net Interest Income+	-1.75M	-1.08M	-88.8K	71.08K	58.81K	-235K	-2.4M	0	-15K	-12K
Interest Income	69.55K	58.84K	70.27K	78.78K	67.73K	0	0	13K	0	0
Interest Expense	1.82M	1.14M	159.07K	7.7K	8.92K	235K	2.4M	13K	15K	12K
Other Income/Expense	-1.75M	-908K	-2.45M	3.33M	280.04K	-1.02M	15.24M	1.46M	770K	421K
Pretax Income+	-20.9M	-21.07M	-15.67M	-4.92M	-8.35M	-10.32M	-26.62M	-14.26M	-12.3M	-14.44M
Pretax Margin %	-2006.72%	-1297.24%	-60.25%	-18.94%	-542.55%	-	-	-	-49.2%	-
Income Tax+	68.83K	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-20.9M	-21.07M	-15.67M	-4.92M	-8.35M	-10.32M	-26.62M	-14.26M	-12.3M	-14.44M
Net Margin %	-2006.72%	-1297.24%	-60.25%	-18.94%	-542.55%	-	-	-	-49.2%	-
Net Income Growth %	0.08%	-0.01%	0.26%	0.69%	-0.7%	-0.24%	-1.58%	0.46%	0.14%	-0.17%
Net Income (Continuing)	-20.9M	-21.07M	-15.67M	-4.92M	-8.35M	-10.32M	-26.62M	-14.26M	-12.3M	-14.44M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-197.36	-126.11	-71.34	-18.02	-35.18	-186.00	-2546.10	-16.53	-27.01	-10.19
EPS Growth %	0.12%	0.36%	0.43%	0.75%	-0.95%	-4.29%	-12.69%	0.99%	-0.63%	0.62%
EPS (Basic)	-197.36	-126.11	-71.59	-18.02	-14.78	-186.00	-2144.25	-16.53	-27.01	-10.19
Diluted Shares Outstanding	105.92K	8.35K	219.6K	273.24K	237.39K	237.39K	12.46K	880.3K	456.01K	1.42M
Basic Shares Outstanding	105.92K	8.35K	218.84K	273.24K	122.41K	832.3K	12.41K	880.1K	456.01K	1.42M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.43M	20.9M	12.45M	6.51M	5.65M	896K	11.51M	14.73M	13.33M	10.49M
Cash & Short-Term Investments	12.23M	20.19M	11.67M	5.79M	5.11M	729K	10.49M	12.38M	12.43M	9.82M
Cash Only	4.72M	15.19M	6.67M	5.79M	5.11M	713K	10.49M	12.38M	12.43M	9.82M
Short-Term Investments	7.52M	5M	5M	0	0	16K	0	0	0	0
Accounts Receivable	37.32K	63.57K	371.59K	358K	21.06K	0	150K	1.44M	148K	24K
Days Sales Outstanding	1.31K	1.43K	521.65	502.57	499.44	-	-	-	216.08	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	100K	0	114K	112K	87K
Total Non-Current Assets+	1.52M	1.7M	1.44M	1.18M	937.01K	2.12M	1.01M	1.03M	724K	386K
Property, Plant & Equipment	343.2K	269.56K	172.89K	90.31K	242.74K	280K	112K	310K	208K	87K
Fixed Asset Turnover	0.03x	0.06x	1.50x	2.88x	0.06x	-	-	-	1.20x	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.1M	990.15K	883.46K	763.54K	668.94K	0	0	0	0	0
Long-Term Investments	0	424.24K	365.46K	298.24K	0	0	0	26K	0	26K
Other Non-Current Assets	71.8K	15.66K	13.85K	23.96K	25.34K	1.84M	894K	694K	516K	273K
Total Assets+	14.95M	22.6M	13.88M	7.68M	6.58M	3.02M	12.51M	15.76M	14.05M	10.88M
Asset Turnover	0.00x	0.00x	0.02x	0.03x	0.00x	-	-	-	0.02x	-
Asset Growth %	-0.5%	0.51%	-0.39%	-0.45%	-0.14%	-0.54%	3.14%	0.26%	-0.11%	-0.23%
Total Current Liabilities+	6.43M	7.33M	1.51M	1.05M	1.22M	8.08M	2.5M	3.01M	2.59M	3.24M
Accounts Payable	1.46M	2.34M	875.07K	832.56K	824.41K	2.54M	1.52M	1.76M	698K	1.1M
Days Payables Outstanding	-	-	-	-306.96	-	6.34K	-	-	-	-
Short-Term Debt	4.63M	3.71M	0	0	0	1.05M	87K	88K	158K	79K
Deferred Revenue (Current)	0	0	0	-1000K	0	0	0	0	0	0
Other Current Liabilities	173.54K	430.74K	220.88K	-756.4K	124.67K	0	511K	574K	831K	0
Current Ratio	2.09x	2.85x	8.22x	6.19x	4.61x	0.11x	4.61x	4.89x	5.15x	3.24x
Quick Ratio	2.09x	2.85x	8.22x	6.19x	4.61x	0.11x	4.61x	4.89x	5.15x	3.24x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.56M	3.94M	3.85M	583.73K	233.14K	2.04M	2.65M	272K	153K	152K
Long-Term Debt	3.38M	0	0	535K	0	94K	0	0	0	0
Capital Lease Obligations	0	0	0	0	148.54K	112K	0	211K	90K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	174.14K	3.94M	3.85M	48.73K	84.59K	1.83M	2.65M	61K	63K	152K
Total Liabilities	9.98M	11.27M	5.37M	1.63M	1.46M	10.12M	5.15M	3.28M	2.74M	3.39M
Total Debt+	7.93M	3.71M	0	5.04M	288.54K	1.42M	199K	404K	369K	169K
Net Debt	3.21M	-11.49M	-6.67M	-749.11K	-4.83M	708K	-10.3M	-11.98M	-12.06M	-9.65M
Debt / Equity	1.60x	0.33x	-	0.83x	0.06x	-	0.03x	0.03x	0.03x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10.55x	-17.67x	-83.08x	-1072.88x	-967.71x	-39.56x	-17.45x	-1209.31x	-871.33x	-1238.25x
Total Equity+	4.97M	11.33M	8.52M	6.05M	5.13M	-7.1M	7.37M	12.48M	11.31M	7.49M
Equity Growth %	-0.72%	1.28%	-0.25%	-0.29%	-0.15%	-2.38%	2.04%	0.69%	-0.09%	-0.34%
Book Value per Share	46.90	1357.79	38.78	22.14	21.59	-29.90	590.95	14.18	24.81	5.29
Total Shareholders' Equity	4.97M	11.33M	8.52M	6.05M	5.13M	-7.1M	7.37M	12.48M	11.31M	7.49M
Common Stock	70.77K	110.33K	151.6K	182.05K	38.66K	28K	3K	30K	93K	27K
Retained Earnings	-171.96M	-193.03M	-208.7M	-213.62M	-221.98M	-68.03M	-94.64M	-109.19M	-121.51M	-135.94M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	3.07K	3.9K	2.63K	-413	-6.19K	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-18.93M	-15.62M	-13.42M	-7.69M	-7.26M	-4.77M	-14.77M	-13.36M	-11.13M	-12.19M
Operating CF Margin %	-1817.38%	-961.23%	-51.6%	-29.59%	-471.33%	-	-	-	-44.53%	-
Operating CF Growth %	-0.62%	0.18%	0.14%	0.43%	0.06%	0.34%	-2.1%	0.1%	0.17%	-0.1%
Net Income	-20.9M	-21.07M	-15.67M	-4.92M	-8.35M	-10.32M	-26.62M	-14.26M	-12.3M	-14.44M
Depreciation & Amortization	345.46K	337.51K	289.21K	185.8K	143.86K	3K	2K	3K	4K	3K
Stock-Based Compensation	2.95M	3.45M	1.77M	1.09M	0	2.01M	1.89M	1.03M	624K	652K
Deferred Taxes	0	0	0	0	0	-38K	0	0	0	0
Other Non-Cash Items	5.37M	3.86M	6.47M	-2.29M	743.83K	1.19M	14.71M	-1.39M	139K	199K
Working Capital Changes	-2.2M	1.51M	-2.15M	-336.88K	208.28K	2.39M	-4.76M	1.25M	400K	1.39M
Change in Receivables	188.21K	-450.5K	-249.23K	80.81K	272.99K	-59K	84K	0	0	0
Change in Inventory	0	-7.91M	-11.75M	36.99K	0	-947K	0	0	0	0
Change in Payables	-1.05M	879.08K	-1.52M	-36.99K	-15.74K	1.01M	0	399K	-492K	818K
Cash from Investing+	7.25M	2.36M	-94.05K	5M	0	-6K	-54K	-10K	-4K	0
Capital Expenditures	-243.58K	-161.11K	-94.05K	-1.71K	0	-6K	0	-10K	-4K	0
CapEx % of Revenue	23.38%	9.92%	0.36%	0.01%	-	-	-	-	0.02%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-67.31K	-63.03K	-82.64K	0	0	0	0	0	0	0
Cash from Financing+	3.89M	23.74M	4.99M	1.81M	6.59M	1.89M	24.61M	15.26M	11.19M	9.58M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-847.05K	0	0	0	0	-87K	-317K	1.65M	2.16M	1.57M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.18M	-15.78M	-13.51M	-7.69M	-7.26M	-4.77M	-14.77M	-13.37M	-11.14M	-12.19M
FCF Margin %	-1840.77%	-971.15%	-51.96%	-29.59%	-471.33%	-	-	-	-44.55%	-
FCF Growth %	-0.56%	0.18%	0.14%	0.43%	0.06%	0.34%	-2.09%	0.09%	0.17%	-0.09%
FCF per Share	-181.04	-1890.62	-61.52	-28.16	-30.56	-20.11	-1185.35	-15.19	-24.42	-8.61
FCF Conversion (FCF/Net Income)	0.91x	0.74x	0.86x	1.56x	0.87x	0.46x	0.56x	0.94x	0.91x	0.84x
Interest Paid	0	0	0	0	0	0	64K	0	0	14K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-184.28%	-258.62%	-157.88%	-67.63%	-149.47%	-	-20012.03%	-143.72%	-103.4%	-153.55%
Return on Invested Capital (ROIC)	-129.64%	-377.18%	-1178.64%	-173.49%	-231.21%	-	-	-	-	-
Gross Margin	100%	100%	100%	480.77%	100%	-	-	-	100%	-
Net Margin	-200671.98%	-129724.24%	-6025.38%	-1894.23%	-54254.9%	-	-	-	-4920%	-
Debt / Equity	1.60x	0.33x	-	0.83x	0.06x	-	0.03x	0.03x	0.03x	0.02x
Interest Coverage	-10.55x	-17.67x	-83.08x	-1072.88x	-967.71x	-39.56x	-17.45x	-1209.31x	-871.33x	-1238.25x
FCF Conversion	0.91x	0.74x	0.86x	1.56x	0.87x	0.46x	0.56x	0.94x	0.91x	0.84x
Revenue Growth	-44.69%	55.96%	1500.39%	0%	-94.08%	-100%	-	-	-	-100%

Frequently Asked Questions

Growth & Financials

Palisade Bio, Inc. (PALI) saw revenue decline by 100.0% over the past year.

Palisade Bio, Inc. (PALI) reported a net loss of $11.2M for fiscal year 2024.

Dividend & Returns

Palisade Bio, Inc. (PALI) has a return on equity (ROE) of -153.6%. Negative ROE indicates the company is unprofitable.

Palisade Bio, Inc. (PALI) had negative free cash flow of $10.1M in fiscal year 2024, likely due to heavy capital investments.